-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MM-402 in Autism Spectrum Disorder (ASD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MM-402 in Autism Spectrum Disorder (ASD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MM-402 in Autism Spectrum Disorder (ASD) Drug Details: Midomafetamine (MM-402)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MM-10001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MM-10001 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MM-10001 in Non-Small Cell Lung Cancer Drug Details: MM-10001 (beta-glucan)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OPC-415 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OPC-415 in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OPC-415 in Relapsed Multiple Myeloma Drug Details: OPC-415 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CS1 Plus BCMA CAR-T in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CS1 Plus BCMA CAR-T in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CS1 Plus BCMA CAR-T in Multiple...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RYZ-101 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RYZ-101 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RYZ-101 in Small-Cell Lung Cancer Drug Details: RYZ-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Temferon in Supratentorial Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Temferon in Supratentorial Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Temferon in Supratentorial Glioma Drug Details: Temferon is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Pembrolizumab + Vibostolimab) in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Pembrolizumab + Vibostolimab) in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Pembrolizumab + Vibostolimab) in Non-Small Cell Lung...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Pembrolizumab + Vibostolimab) in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Pembrolizumab + Vibostolimab) in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Pembrolizumab + Vibostolimab) in Metastatic Renal Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Selinexor in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Selinexor in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Selinexor in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) Drug...